178 related articles for article (PubMed ID: 19417657)
1. Diagnostic value of T-cell monitoring assays in kidney transplantation.
Nickel P; Bestard O; Volk HD; Reinke P
Curr Opin Organ Transplant; 2009 Aug; 14(4):426-31. PubMed ID: 19417657
[TBL] [Abstract][Full Text] [Related]
2. ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring--even in hands of ELISPOT-inexperienced investigators.
Zhang W; Caspell R; Karulin AY; Ahmad M; Haicheur N; Abdelsalam A; Johannesen K; Vignard V; Dudzik P; Georgakopoulou K; Mihaylova A; Silina K; Aptsiauri N; Adams V; Lehmann PV; McArdle S
J Immunotoxicol; 2009 Dec; 6(4):227-34. PubMed ID: 19908941
[TBL] [Abstract][Full Text] [Related]
3. Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients.
Couzi L; Thiébaut R; Carron JC; Moreau JF; Merville P; Taupin JL
Transplantation; 2008 Oct; 86(8):1060-7. PubMed ID: 18946343
[TBL] [Abstract][Full Text] [Related]
4. Modified ELISPOT technique--highly significant inverse correlation of post-Tx donor-reactive IFNgamma-producing cell frequencies with 6 and 12 months graft function in kidney transplant recipients.
Näther BJ; Nickel P; Bold G; Presber F; Schönemann C; Pratschke J; Volk HD; Reinke P
Transpl Immunol; 2006 Nov; 16(3-4):232-7. PubMed ID: 17138059
[TBL] [Abstract][Full Text] [Related]
5. Quantification of T-cell proliferation for individualizing immunosuppressive therapy for transplantation patients.
Ohdan H
Clin Pharmacol Ther; 2010 Jan; 87(1):23-6. PubMed ID: 20019698
[TBL] [Abstract][Full Text] [Related]
6. Failure of immunosuppressive drug levels to predict T-cell reactivity in pediatric transplant patients.
Sampson VB; Dunn SP; Rymeski B; Malatack J; Rong NH; Flynn L; Krueger LJ
J Pediatr Surg; 2008 Jun; 43(6):1134-41. PubMed ID: 18558196
[TBL] [Abstract][Full Text] [Related]
7. Review: Pharmacodynamic monitoring of immunosuppression in kidney transplantation.
Barraclough KA; Staatz CE; Isbel NM; McTaggart SJ
Nephrology (Carlton); 2010 Aug; 15(5):522-32. PubMed ID: 20649871
[TBL] [Abstract][Full Text] [Related]
8. Monitoring alloimmune response in kidney transplantation.
Bestard O; Cravedi P
J Nephrol; 2017 Apr; 30(2):187-200. PubMed ID: 27245689
[TBL] [Abstract][Full Text] [Related]
9. Pretransplant immune risk assessment.
Sawitzki B; Schlickeiser S; Reinke P; Volk HD
Curr Opin Organ Transplant; 2009 Dec; 14(6):650-5. PubMed ID: 19779344
[TBL] [Abstract][Full Text] [Related]
10. Tolerance assays: measuring the unknown.
Newell KA; Larsen CP
Transplantation; 2006 Jun; 81(11):1503-9. PubMed ID: 16770237
[TBL] [Abstract][Full Text] [Related]
11. Comparison of several functional methods to evaluate the immune response on stable kidney transplant patients.
Martínez-Flores JA; Serrano M; Morales P; Paz-Artal E; Morales JM; Serrano A
J Immunol Methods; 2014 Jan; 403(1-2):62-5. PubMed ID: 24291342
[TBL] [Abstract][Full Text] [Related]
12. T-cell immune monitoring by the ELISPOT assay for interferon gamma.
Augustine JJ; Hricik DE
Clin Chim Acta; 2012 Sep; 413(17-18):1359-63. PubMed ID: 22732764
[TBL] [Abstract][Full Text] [Related]
13. Can we use biomarkers and functional assays to implement personalized therapies in transplantation?
Sawitzki B; Pascher A; Babel N; Reinke P; Volk HD
Transplantation; 2009 Jun; 87(11):1595-601. PubMed ID: 19502949
[TBL] [Abstract][Full Text] [Related]
14. Novel noninvasive assays to predict transplantation rejection and tolerance: enumeration of cytokine-producing alloreactive T cells.
Benítez F; Najafian N
Clin Lab Med; 2008 Sep; 28(3):365-73, v. PubMed ID: 19028257
[TBL] [Abstract][Full Text] [Related]
15. Immune monitoring of T-cell responses in cancer vaccine development.
Keilholz U; Martus P; Scheibenbogen C
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2346s-2352s. PubMed ID: 16609057
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers in renal transplantation.
Bestard O; Cruzado JM; la Franquesa M; Grinyó JM
Curr Opin Organ Transplant; 2010 Aug; 15(4):467-73. PubMed ID: 20613522
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of indirect allorecognition: wishful thinking or solid data?
Waanders MM; Heidt S; Koekkoek KM; Zoet YM; Doxiadis II; Amir A; Heemskerk MH; Mulder A; Brand A; Roelen DL; Claas FH
Tissue Antigens; 2008 Jan; 71(1):1-15. PubMed ID: 18096006
[TBL] [Abstract][Full Text] [Related]
18. Human CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigm.
Lúcia M; Crespo E; Cruzado JM; Grinyó JM; Bestard O
Transpl Int; 2014 Jul; 27(7):643-56. PubMed ID: 24629072
[TBL] [Abstract][Full Text] [Related]
19. Cell mediated immunity (CMI) and post transplant viral infections--role of a functional immune assay to titrate immunosuppression.
Gautam A; Fischer SA; Yango AF; Gohh RY; Morrissey PE; Monaco AP
Int Immunopharmacol; 2006 Dec; 6(13-14):2023-6. PubMed ID: 17161357
[TBL] [Abstract][Full Text] [Related]
20. Cytokines as predictive biomarkers of alloreactivity.
Brunet M
Clin Chim Acta; 2012 Sep; 413(17-18):1354-8. PubMed ID: 22561186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
